Released Nov 5, 2026, before the open
10-Q filed Nov 5, 2026, 36 days after period end · 0001193125-26-448543
What the release said
The California Institute for Regenerative Medicine (CIRM) awarded the Company a $15.0 million grant through its CLIN2 program to support the clinical development of RECLAIM-LN.
Fate Therapeutics reported a net loss of $30.7 million, or $(0.25) per share, for the third quarter of 2026, compared with $32.3 million, or $(0.27) per share, for the third quarter of 2025.¶2
Cash, cash equivalents, and investments were $139.1 million as of September 30, 2026, a quarterly decrease of $14.7 million, and the company said this extends its cash runway to mid-2028 with the new grant.¶3¶4
The California Institute for Regenerative Medicine awarded the company a $15.0 million CLIN2 grant to support the clinical development of RECLAIM-LN.¶1
Across 29 autoimmune patients treated with a single dose of FT819 as of an August 18, 2026 data cutoff, Grade 1–2 cytokine release syndrome occurred in 5 patients (17.2%).¶5¶6
- Net loss, third quarter 2026
- $30.7 million Compared with $32.3 million for the third quarter of 2025¶2
- Net loss per share, third quarter 2026
- $(0.25) Compared with $(0.27) per share for the third quarter of 2025¶2
- Cash, cash equivalents, and investments
- $139.1 million As of September 30, 2026; a quarterly decrease of $14.7 million¶3
- Total operating expenses
- $32.2 million For the third quarter of 2026¶7
- CIRM CLIN2 grant
- $15.0 million Awarded to support RECLAIM-LN¶1
Same quarter
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $0.00 | $1.74M | $3.07M | $1.94M |
| Net Income | -$30.69M | -$32.25M | -$47.68M | -$45.17M |
| EPS Diluted | -$0.25 | -$0.27 | -$0.40 | -$0.46 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR